- Home
- NMRK vs IBRX Comparison
NMRK vs IBRX Comparison
Compare NMRK & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- IBRX
- Stock Information
- Founded
- NMRK 1929
- IBRX 2014
- Country
- NMRK United States
- IBRX United States
- Employees
- NMRK N/A
- IBRX N/A
- Industry
- NMRK Real Estate
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMRK Finance
- IBRX Health Care
- Exchange
- NMRK Nasdaq
- IBRX Nasdaq
- Market Cap
- NMRK 2.2B
- IBRX 2.3B
- IPO Year
- NMRK 2017
- IBRX N/A
- Fundamental
- Price
- NMRK $13.20
- IBRX $2.89
- Analyst Decision
- NMRK Strong Buy
- IBRX Strong Buy
- Analyst Count
- NMRK 5
- IBRX 5
- Target Price
- NMRK $16.00
- IBRX $11.40
- AVG Volume (30 Days)
- NMRK 1.2M
- IBRX 6.4M
- Earning Date
- NMRK 07-30-2025
- IBRX 08-11-2025
- Dividend Yield
- NMRK 0.94%
- IBRX N/A
- EPS Growth
- NMRK 81.01
- IBRX N/A
- EPS
- NMRK 0.38
- IBRX N/A
- Revenue
- NMRK $2,857,497,000.00
- IBRX $31,222,000.00
- Revenue This Year
- NMRK $13.78
- IBRX $567.98
- Revenue Next Year
- NMRK $9.47
- IBRX $160.56
- P/E Ratio
- NMRK $33.72
- IBRX N/A
- Revenue Growth
- NMRK 14.48
- IBRX 10238.41
- 52 Week Low
- NMRK $9.65
- IBRX $1.83
- 52 Week High
- NMRK $16.10
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- NMRK 64.96
- IBRX 49.08
- Support Level
- NMRK $12.06
- IBRX $2.64
- Resistance Level
- NMRK $12.63
- IBRX $2.94
- Average True Range (ATR)
- NMRK 0.34
- IBRX 0.15
- MACD
- NMRK 0.01
- IBRX -0.00
- Stochastic Oscillator
- NMRK 94.18
- IBRX 31.94
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.